Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2

The study "P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2" evaluated the effectiveness of baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, in treating severe alopecia areata (AA) over 52 weeks. The study included 855 patients who were randomized to receive either 2mg or 4mg of baricitinib. The severity of AA was categorized as severe (SALT score 50–94) or very severe (SALT score 95–100). At week 52, a SALT score ≤ 20 was achieved by 36.1% and 51.2% of patients on baricitinib 2mg and 4mg, respectively, with severe AA and 12.4% and 27.7% of patients on baricitinib 2mg and 4mg, respectively, with very severe AA. The study concluded that baricitinib showed efficacy in treating both severe and very severe AA, with similar proportions of patients achieving full coverage or minimal gaps in eyebrows and eyelashes at week 52, regardless of scalp hair-loss severity.